Pipeline
Initial Targeted Indications
Indication | Targeted Subgroup | Formulation | Unique selling point (USP) |
|---|---|---|---|
© Dale Biotech LLC 2021. All Rights Reserved. | |||
Non-alcoholic Steatohepatitis (NASH) | NASH patients especially those with diabetes | Oral | Combination therapy addresses the multiple drivers of NASH progression to cirrhosis and liver failure driven by endothelial disfunction and inflammation. These factors also drive cardiovascular risk and peripheral artery disease, and increased risk of severe COVID-19. Niclosamide has potent efficacy against virus variants of COVID-19. |
Additional Development Opportunities
Indication | Targeted Subgroup | Formulation | Unique selling point (USP) |
|---|---|---|---|
© Dale Biotech LLC 2021. All rights reserved. | |||
Body Sculpting | Double chin | Injectable | Significantly less inflammation than currently marketed injectable; Single treatment efficacy expected to be sufficient in majority of clients |
Central abdominal bulge | Injectable | No available injectable | |
Dupuytren’s Disease | Progressive contractures post hand surgery or Xiaflex injection(s) | Injectable sustained release | Large unmet medical need for effective disease modifying treatment |
Progressive contractures post hand surgery or Xiaflex injection(s) | Topical | Large market for effective treatment that can be patient-administered | |
Cellulite | Cellulite of lateral and posterior buttocks | Subcutaneous-injectable | Direct action of adipocytes |